Bevacizumab

Evidence Level: L5

Predicted Indications: 10

Bevacizumab

Pharmacist Assessment Report

Bevacizumab: anti-VEGF-A monoclonal antibody → epiglottis neoplasm

One-Sentence Summary

Bevacizumab is a monoclonal antibody that neutralizes VEGF-A and inhibits tumour angiogenesis. The TxGNN model predicts it may be effective for epiglottis neoplasm, with a prediction score of 0.9990. No clinical trials or publications were retrieved for this specific disease, so the prediction currently rests on the model alone.

Quick Overview

Item	Content
Original Indication	Not recorded in the local data
Predicted New Indication	epiglottis neoplasm
TxGNN Prediction Score	0.9990
Evidence Level	L5
Canada Market Status	Marketed (marketed DINs: 13 of 13)
Number of DINs	13 (marketed: 13)
Recommended Decision	Hold

Why is This Prediction Reasonable?

Bevacizumab binds and neutralizes VEGF-A, which reduces the formation of new blood vessels that tumours need to grow. Detailed mechanism-of-action data are not available in the data compiled for this report, so this description reflects the general, well-known action of the drug.

Neoplasms of the head and neck region, including the epiglottis, depend on angiogenesis like many other solid tumours. This offers a plausible, but generic, mechanistic rationale for the prediction. No study retrieved for this report examines bevacizumab in epiglottis neoplasm, so the link has not been tested in the data available here.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Canada Market Information

DIN	Product Name	Dosage Form	Approved Indication
02520737	BAMBEVI	Not recorded	Not recorded
02522829	AYBINTIO	Not recorded	Not recorded
02489430	ZIRABEV	Not recorded	Not recorded
02534185	VEGZELMA	Not recorded	Not recorded
02270994	AVASTIN	Not recorded	Not recorded

All 13 licences in the local data are valid single-ingredient authorizations, and the list above shows five of them.

Cytotoxicity

Item	Content
Cytotoxicity Classification	Targeted therapy (anti-VEGF monoclonal antibody), not a conventional cytotoxic
Myelosuppression Risk	Please refer to the package insert warnings and precautions
Emetogenicity Classification	Please refer to the package insert warnings and precautions
Monitoring Items	Blood pressure, urine protein, signs of bleeding, gastrointestinal perforation and wound-healing problems; please also refer to the package insert
Handling Protection	Please refer to the package insert warnings and precautions

Safety Considerations

Drug Interactions: 22 interactions were recorded. Major-level interactions include deferiprone, samarium (153Sm) lexidronam, panitumumab, sunitinib and thalidomide. Moderate-level interactions include bisphosphonates (alendronic acid, risedronic acid, etidronic acid, ibandronate, pamidronic acid, tiludronic acid), filgrastim, pegfilgrastim, sargramostim, palifermin, idelalisib, romosozumab, strontium chloride Sr-89, radium Ra 223 dichloride and monobasic sodium phosphate (P32).

Please refer to the package insert for warnings and contraindications.

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction score is high, but no clinical trials or publications directly address epiglottis neoplasm, so the evidence level is L5 and the mechanistic rationale is only generic.

To proceed, the following is needed:

Searches for direct clinical or preclinical studies of bevacizumab in epiglottis and laryngeal neoplasms
Mechanism-of-action data and package insert warnings and contraindications from Health Canada
A safety review of the major drug interactions, particularly with other anti-angiogenic and targeted agents
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.